Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Sarepta’s gene therapy for Duchenne muscular ... In particular, it highlighted “compelling” improvements over placebo on secondary endpoints like improvements in time to rise from the ...

Lumin Digital, a leading cloud-native digital banking provider, today announced that clients have invested over $75 million into the business, highlighting a dedication to partnership in which clients ...

There were, however, significant improvements on secondary measures, including time to rise and a 10-metre walk test that, according to Sarepta, were “evidence of a clinically meaningful benefit ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...

A patient died from liver injury while taking the gene therapy Elevidys Sarepta says more than 800 patients have received the treatment The company plans to update prescribing information after ...

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic ...

To further muddy the waters, card reviews and advertising generally label the insurance as primary or secondary. Before applying for a card, it’s worth knowing the differences between these ...